MDT - Medtronic PLC Stock Price, Fair Value and News

79.58USD-0.80 (-1.00%)Delayed as of 25 Apr 2024, 09:59 am ET

Market Summary

USD79.58-0.80

Delayedas of 25 Apr 2024, 09:59 am

-1.00%

MDT Stock Price

View Fullscreen

MDT RSI Chart

MDT Valuation

Market Cap

106.7B

Price/Earnings (Trailing)

25.38

Price/Sales (Trailing)

3.3

EV/EBITDA

14.51

Price/Free Cashflow

21.64

MDT Price/Sales (Trailing)

MDT Profitability

EBT Margin

17.12%

Return on Equity

8.12%

Return on Assets

4.63%

Free Cashflow Yield

4.62%

MDT Fundamentals

MDT Revenue

Revenue (TTM)

32.3B

Rev. Growth (Yr)

4.68%

Rev. Growth (Qtr)

1.32%

MDT Earnings

Earnings (TTM)

4.2B

Earnings Growth (Yr)

8.18%

Earnings Growth (Qtr)

45.12%

Breaking Down MDT Revenue

52 Week Range

75.5092.02

(Low)(High)

Last 7 days

1.6%

Last 30 days

-3.4%

Last 90 days

-6.3%

Trailing 12 Months

-10.4%

How does MDT drawdown profile look like?

MDT Financial Health

Current Ratio

2.3

Debt/Equity

0.47

Debt/Cashflow

0.27

MDT Investor Care

Dividend Yield

3.42%

Dividend/Share (TTM)

2.75

Buy Backs (1Y)

0.20%

Diluted EPS (TTM)

3.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	32.3B	0	0	0
2023	30.8B	31.2B	31.6B	32.0B
2022	31.8B	31.7B	31.1B	30.8B
2021	27.9B	30.1B	31.6B	31.8B
2020	31.1B	28.9B	27.9B	27.9B
2019	30.6B	30.6B	30.7B	30.9B
2018	29.7B	30.0B	29.9B	30.4B
2017	29.4B	29.7B	29.9B	29.6B
2016	28.6B	28.8B	28.7B	29.0B
2015	17.5B	20.3B	23.3B	26.0B
2014	16.9B	17.0B	17.2B	17.4B
2013	16.5B	16.6B	16.7B	16.8B
2012	0	16.2B	16.3B	16.4B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Medtronic PLC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	marinaro michael	sold	-71,001	83.14	-854	evp & president, surgical ou
Mar 05, 2024	marinaro michael	sold (taxes)	-47,066	83.6	-563	evp & president, surgical ou
Feb 21, 2024	salmon sean	acquired	2,120,120	69.0706	30,695	evp & president cardiovascular
Feb 21, 2024	salmon sean	sold	-2,613,050	85.1297	-30,695	evp & president cardiovascular
Feb 01, 2024	kirk jennifer m	sold (taxes)	-102,096	88.09	-1,159	chief accounting officer
Dec 19, 2023	wall brett a.	sold	-410,604	82.17	-4,997	evp & pres neuroscience
Dec 11, 2023	fong ivan k	sold (taxes)	-154,891	79.35	-1,952	evp general counsel & secr
Dec 08, 2023	fong ivan k	sold (taxes)	-56,757	79.27	-716	evp general counsel & secr
Dec 08, 2023	wall brett a.	sold (taxes)	-34,482	79.27	-435	evp & pres neuroscience
Dec 08, 2023	salmon sean	sold (taxes)	-34,482	79.27	-435	evp & president cardiovascular

Which funds bought or sold MDT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	BSW Wealth Partners	reduced	-13.24	-64,058	715,872	0.12%
Apr 23, 2024	EADS & HEALD WEALTH MANAGEMENT	reduced	-18.32	-72,000	462,000	0.22%
Apr 23, 2024	United Asset Strategies, Inc.	added	32.25	2,364,160	8,288,430	0.83%
Apr 23, 2024	NATIONS FINANCIAL GROUP INC, /IA/ /ADV	reduced	-63.82	-1,094,150	678,416	0.06%
Apr 23, 2024	Morton Brown Family Wealth, LLC	sold off	-100	-3,542	-	-%
Apr 23, 2024	Venturi Wealth Management, LLC	reduced	-79.22	-273,483	77,045	-%
Apr 23, 2024	Charter Oak Capital Management, LLC	added	1.47	109,314	1,597,920	0.17%
Apr 23, 2024	REGIONS FINANCIAL CORP	reduced	-1.09	178,039	4,017,440	0.03%
Apr 23, 2024	Leverty Financial Group, LLC	unchanged	-	19,147	349,820	0.21%
Apr 23, 2024	RATIONAL ADVISORS LLC	reduced	-97.22	-2,147,470	65,014	0.01%

Are Funds Buying or Selling MDT?

Are funds buying MDT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MDT

No. of Funds

Unveiling Medtronic PLC's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.52%	126,545,940	SC 13G/A
Feb 12, 2024	blackrock inc.	8.9%	118,570,867	SC 13G/A
Feb 15, 2023	blackrock inc.	9.2%	122,349,678	SC 13G/A
Feb 09, 2023	vanguard group inc	9.41%	125,126,702	SC 13G/A
Feb 01, 2022	blackrock inc.	8.0%	107,903,361	SC 13G/A
Feb 10, 2021	vanguard group inc	8.27%	111,286,018	SC 13G/A
Feb 03, 2021	wellington management group llp	2.87%	38,648,749	SC 13G/A
Jan 29, 2021	blackrock inc.	7.96%	107,107,760	SC 13G/A
Feb 12, 2020	vanguard group inc	8.55%	114,617,479	SC 13G/A
Feb 05, 2020	blackrock inc.	8.2%	109,561,921	SC 13G/A

Recent SEC filings of Medtronic PLC

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Feb 27, 2024	10-Q	Quarterly Report
Feb 23, 2024	4	Insider Trading
Feb 21, 2024	144	Notice of Insider Sale Intent
Feb 20, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	5	Insider Trading
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 12, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Medtronic PLC)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.82%	-2.78%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-3.26%	-10.41%	53.77	3.46	4.02%	-22.04%
ALGN	23.6B	3.9B	-1.72%	-10.74%	52.95	6.1	3.42%	23.09%
BAX	20.8B	14.8B	-2.03%	-9.90%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	0.44%	-12.46%	22.62	0.76	-2.44%	-22.68%
ATR	9.2B	3.5B	-2.07%	18.57%	32.49	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.49%	-36.41%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.85%	-24.53%	-47.67	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-3.04%	14.62%	-560.04	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-3.54%	-1.62%	12.12	0.36	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-13.37%	-14.88%	-1.92	0.41	7.73%	-1066.14%
ANIK	384.6M	166.7M	3.23%	-3.00%	-4.65	2.31	6.67%	-456.34%
ANGO	235.1M	324.0M	11.39%	-31.43%	-1.22	0.73	-3.19%	-337.41%
APYX	52.0M	52.3M	18.11%	-48.10%	-2.78	0.99	17.61%	19.28%
AEMD	4.0M	3.7M	-12.07%	240.00%	-0.33	1.07	5.77%	8.23%

Medtronic PLC News

Latest updates

Medtronic PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	1.3%	8,089	7,984	7,702	8,545	7,727	7,585	7,371	8,089	7,763	7,847	7,987	8,188	7,775	7,647	6,507	5,998	7,717	7,706	7,493	8,146	7,546
S&GA Expenses	-0.5%	2,673	2,686	2,613	2,616	2,615	2,617	2,567	2,569	2,561	2,615	2,547	2,595	2,537	2,600	2,417	2,359	2,587	2,620	2,543	2,620	2,596
EBITDA Margin	-0.1%	0.28*	0.28*	0.28*	0.28*	0.28*	0.29*	0.29*	0.28*	0.27*	0.26*	0.24*	0.25*	-	-	-	-	-	-	-	-	-
Interest Expenses	4.4%	188	180	148	187	167	118	164	143	137	136	137	142	143	470	171	162	156	165	609	718	243
Income Taxes	-66.4%	135	402	400	363	146	959	112	110	106	176	64.00	200	-59.00	31.00	93.00	-434	-340	-77.00	100	110	99.00
Earnings Before Taxes	12.1%	1,472	1,313	1,196	1,551	1,375	1,395	1,044	1,602	1,589	1,493	833	1,566	1,220	525	584	205	1,579	1,294	977	1,292	1,370
EBT Margin	0.6%	0.17*	0.17*	0.17*	0.17*	0.18*	0.18*	0.18*	0.17*	0.17*	0.16*	0.13*	0.13*	-	-	-	-	-	-	-	-	-
Net Income	45.1%	1,322	911	797	1,175	1,222	435	931	1,479	1,480	1,317	769	1,356	1,270	494	491	646	1,915	1,371	877	1,172	1,269
Net Income Margin	1.3%	0.13*	0.13*	0.11*	0.12*	0.13*	0.14*	0.17*	0.16*	0.15*	0.15*	0.12*	0.12*	-	-	-	-	-	-	-	-	-
Free Cashflow	964.0%	2,128	200	521	2,082	1,242	599	657	1,668	1,898	1,498	914	1,368	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	0.8%	90,836	90,087	90,776	90,948	94,134	93,241	89,914	90,981	91,804	91,756	91,802	93,083	97,270	95,886	93,906	90,689	92,822	91,053	91,268	89,694	88,730
Current Assets	2.0%	22,513	22,081	21,869	21,675	25,364	25,398	22,135	23,059	23,303	22,731	22,434	22,548	26,347	26,036	24,509	22,031	24,043	22,653	22,705	21,967	20,877
Cash Equivalents	23.8%	1,623	1,311	1,339	1,543	4,521	4,828	2,140	3,714	3,479	2,900	3,004	3,593	5,077	6,420	6,499	4,140	3,709	3,962	5,080	4,393	3,703
Inventory	-0.5%	5,726	5,754	5,668	5,293	5,375	5,055	4,809	4,616	4,514	4,349	4,288	4,313	4,508	4,484	4,551	4,229	4,122	4,042	3,932	3,753	3,866
Net PPE	1.8%	5,838	5,735	5,665	5,569	5,437	5,298	5,281	5,413	5,251	5,188	5,162	5,221	5,023	4,938	4,882	4,828	4,764	4,756	4,711	4,675	4,593
Goodwill	0.8%	41,160	40,821	41,436	41,425	66.00	66.00	66.00	615	80.00	80.00	41,720	41,961	805	381	40,714	39,841	92.00	92.00	65.00	39,959	146
Liabilities	1.0%	38,840	38,440	39,410	39,283	42,516	41,184	37,071	38,260	39,091	39,596	40,137	41,481	46,342	45,570	43,463	39,817	40,869	40,334	40,771	39,482	38,789
Current Liabilities	1.4%	9,793	9,659	9,047	9,051	14,422	14,465	14,049	12,394	8,927	7,803	7,764	8,509	12,534	12,071	13,086	10,366	8,735	8,170	8,518	8,472	8,853
Long Term Debt	1.7%	24,153	23,741	24,463	24,344	22,210	20,753	17,481	20,372	24,290	25,607	25,958	26,378	26,502	25,967	22,867	22,021	24,732	24,752	24,804	24,486	23,674
Shareholder's Equity	0.3%	51,792	51,647	51,366	51,483	51,618	52,057	52,843	52,722	52,713	52,159	51,664	51,602	50,928	50,316	50,443	50,872	51,953	50,719	50,497	50,212	49,941
Retained Earnings	1.3%	30,661	30,256	30,265	30,392	30,117	29,799	30,276	30,250	29,607	28,974	28,511	28,594	28,015	27,526	27,817	28,132	28,210	27,018	26,377	26,270	25,769
Additional Paid-In Capital	0.0%	24,589	24,580	24,587	24,590	24,513	24,442	24,335	24,566	25,814	26,059	26,184	26,319	26,665	26,481	26,261	26,165	26,144	26,171	26,470	26,532	26,518
Accumulated Depreciation	-	-	-	-	-	8,489	8,199	8,043	7,952	7,823	7,790	7,646	7,479	7,375	7,260	7,070	6,816	6,743	6,608	6,425	6,245	6,153
Shares Outstanding	0.0%	1,330	1,330	1,330	1,331	1,330	1,329	1,329	1,331	1,344	1,345	1,345	1,345	-	-	-	-	-	-	-	-	-
Minority Interest	9.1%	204	187	188	182	177	177	170	171	171	168	178	174	170	152	147	135	145	141	134	121	112
Float	-	-	-	-	-	-	115,500	-	-	-	161,200	-	-	-	135,300	-	-	-	141,300	-	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	274.3%	2,474	661	875	2,460	1,574	922	1,083	2,057	2,228	1,769	1,292	1,745	2,356	1,861	278	1,450	2,407	1,867	1,510	2,087	2,055
Share Based Compensation	-41.8%	85.00	146	73.00	75.00	81.00	137	62.00	72.00	78.00	140	69.00	69.00	65.00	140	70.00	62.00	66.00	108	61.00	62.00	60.00
Cashflow From Investing	-66.7%	-707	-424	-539	-475	-287	-1,146	-1,585	271	-437	-709	-784	1,919	-2,773	-2,020	8.00	365	-1,801	-1,216	-551	-529	-1,009
Cashflow From Financing	-1566.7%	-1,500	-90.00	-501	-4,890	-2,134	3,014	-950	-1,949	-1,177	-1,155	-1,055	-5,129	-998	32.00	1,959	-1,310	-873	-1,741	-274	-860	-1,268
Dividend Payments	-0.1%	917	918	918	905	904	904	903	843	847	847	846	781	781	780	778	724	723	723	724	671	671
Buy Backs	-34.4%	124	189	148	131	63.00	85.00	333	1,455	372	358	311	575	9.00	68.00	-	164	236	552	328	182	672

MDT Income Statement

2024-01-26

Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions	3 Months Ended		9 Months Ended
	Jan. 26, 2024	Jan. 27, 2023	Jan. 26, 2024	Jan. 27, 2023
Income Statement [Abstract]
Net sales	$ 8,089,000,000	$ 7,727,000,000	$ 23,775,000,000	$ 22,682,000,000
Costs and expenses:
Cost of products sold, excluding amortization of intangible assets	2,782,000,000	2,689,000,000	8,172,000,000	7,740,000,000
Research and development expense	695,000,000	688,000,000	2,060,000,000	2,055,000,000
Selling, general, and administrative expense	2,673,000,000	2,615,000,000	7,971,000,000	7,799,000,000
Amortization of intangible assets	419,000,000	431,000,000	1,274,000,000	1,275,000,000
Restructuring charges, net	20,000,000	38,000,000	114,000,000	81,000,000
Certain litigation charges	0	0	105,000,000	0
Other operating expense (income), net	17,000,000	(125,000,000)	(13,000,000)	(187,000,000)
Operating profit	1,483,000,000	1,392,000,000	4,091,000,000	3,920,000,000
Other non-operating income, net	(177,000,000)	(149,000,000)	(407,000,000)	(342,000,000)
Interest expense, net	188,000,000	167,000,000	517,000,000	449,000,000
Income before income taxes	1,472,000,000	1,375,000,000	3,982,000,000	3,813,000,000
Income tax provision	135,000,000	146,000,000	936,000,000	1,218,000,000
Net income	1,337,000,000	1,229,000,000	3,045,000,000	2,595,000,000
Net income attributable to noncontrolling interests	(15,000,000)	(6,000,000)	(23,000,000)	(17,000,000)
Net income attributable to Medtronic	$ 1,322,000,000	$ 1,222,000,000	$ 3,022,000,000	$ 2,579,000,000
Basic earnings per share (usd per share)	$ 0.99	$ 0.92	$ 2.27	$ 1.94
Diluted earnings per share (usd per share)	$ 0.99	$ 0.92	$ 2.27	$ 1.94
Basic weighted average shares outstanding (shares)	1,329.7	1,330.2	1,330.1	1,329.6
Diluted weighted average shares outstanding (shares)	1,331.7	1,332.0	1,332.4	1,332.8

MDT Balance Sheet

2024-01-26

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jan. 26, 2024	Apr. 28, 2023
Current assets:
Cash and cash equivalents	$ 1,623	$ 1,543
Investments	6,698	6,416
Accounts receivable, less allowances and credit losses of $180 and $176, respectively	5,968	5,998
Inventories, net	5,726	5,293
Other current assets	2,499	2,425
Total current assets	22,513	21,675
Property, plant, and equipment, net	5,838	5,569
Goodwill	41,160	41,425
Other intangible assets, net	13,690	14,844
Tax assets	3,599	3,477
Other assets	4,036	3,959
Total assets	90,836	90,948
Current liabilities:
Current debt obligations	1,029	20
Accounts payable	1,992	2,662
Accrued compensation	2,174	1,949
Accrued income taxes	1,109	840
Other accrued expenses	3,488	3,581
Total current liabilities	9,793	9,051
Long-term debt	24,153	24,344
Accrued compensation and retirement benefits	1,049	1,093
Accrued income taxes	1,821	2,360
Deferred tax liabilities	615	708
Other liabilities	1,410	1,727
Total liabilities	38,840	39,283
Commitments and contingencies (Note 16)
Shareholders’ equity:
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,329,653,024 and 1,330,809,036 shares issued and outstanding, respectively	0	0
Additional paid-in capital	24,589	24,590
Retained earnings	30,661	30,392
Accumulated other comprehensive loss	(3,459)	(3,499)
Total shareholders’ equity	51,792	51,483
Noncontrolling interests	204	182
Total equity	51,996	51,665
Total liabilities and equity	$ 90,836	$ 90,948

About Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

CEO	Mr. Geoffrey Straub Martha
WEBSITE	medtronic.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	65535

Medtronic PLC Frequently Asked Questions

What is the ticker symbol for Medtronic PLC? What does MDT stand for in stocks?

MDT is the stock ticker symbol of Medtronic PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Medtronic PLC (MDT)?

As of Wed Apr 24 2024, market cap of Medtronic PLC is 106.73 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MDT stock?

You can check MDT's fair value in chart for subscribers.

What is the fair value of MDT stock?

You can check MDT's fair value in chart for subscribers. The fair value of Medtronic PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Medtronic PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MDT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Medtronic PLC a good stock to buy?

The fair value guage provides a quick view whether MDT is over valued or under valued. Whether Medtronic PLC is cheap or expensive depends on the assumptions which impact Medtronic PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MDT.

What is Medtronic PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, MDT's PE ratio (Price to Earnings) is 25.38 and Price to Sales (PS) ratio is 3.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MDT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Medtronic PLC's stock?

In the past 10 years, Medtronic PLC has provided 0.051 (multiply by 100 for percentage) rate of return.